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Recent ﬁndings showed the presence of a reciprocal relationship between thyroid hor-
mones and ghrelin, although the exact mechanism is not known. Design: Our study is
addressed to evaluate the effect of acute exogenous rhTSH administration on serumghrelin
levels in athyreotic patients on replacement l-thyroxine therapy. The study group included
50 patients (16 males and 34 females) submitted to total thyroidectomy and 131-iodine
remnant ablation for differentiated thyroid cancer on l-thyroxine therapy. Mean age was
47.5± 16.5 years and mean BMI was 25.6± 5.01 kg/m2. rhTSH was administrated at the
dosage of 0.9mg i.m. once daily for two consecutive days. Blood samples were taken
between 08.00 and 09.00 after a overnight fasting for measurement ofTSH, FT3, FT4, and
ghrelin before the ﬁrst administration of rhTSH and for measurement of TSH and ghrelin
24, 48, 72, and 96 h after the ﬁrst administration of rhTSH. Results: Mean±SD values
of basal TSH were 0.54± 0.77μU/ml without signiﬁcant difference between females and
males. As expected, after rhTSH administration TSH concentrations increased at 24 and
48 hwith peakTSHvalues ranging from20.20 to 313μU/ml (mean±SD98.4± 66.7μU/ml).
Mean±SD values of basal ghrelin were 1085± 373 pg/ml without signiﬁcant difference
between males and females. After rhTSH administration ghrelin concentrations decreased
signiﬁcantly (p< 0.01) at 24 h (mean±SD 934± 314 pg/ml p< 0.01) and returned to pre-
treatment levels at 96 h. Conclusion: Our study demonstrates that acute exogenousTSH
administration has a suppressive effect on ghrelin secretion independent from changes in
thyroid status.
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INTRODUCTION
Ghrelin, an acylated 28-amino acid ligand for the growth hor-
mone secretagogue receptor (GHS-R), is produced principally
by the neuroendocrine X/A cells of the gastric mucosa (Kojima
and Kangawa, 2005). It was also identiﬁed in the pituitary gland,
hypothalamus, pancreas, and others tissues (Date and Kojima,
2000). At the hypothalamic level, ghrelin stimulates GH release
and regulates appetite and energy balance (Waren and Small,
2000; Ghigo and Arvat, 2001). Increased levels are seen in cata-
bolic conditions (Misra andMiller, 2005), and decreased levels are
found in obese patients (Marchesini andBianchi, 2004).Moreover,
an inverse correlation between serum ghrelin levels and resting
energy expenditure (REE) has been recorded in healthy women
(Kamiji and Troncon, 2010). Thyroid disease is associated with
changes in appetite, food intake, and REE. Previous studies have
reported decreased levels of ghrelin in hyperthyroidism (Altinova
and Toruner, 2006a) and increased levels in hypothyroid patients
(Gjedde and Vestergaard, 2008; Kosowicz and Baumann-Antczak,
2011). On the other hand it has been recently demonstrated the
presence of mRNA of GHS-R in thyroid tissues (Ueberberg and
Abbreviations: BMI, body mass index; GHS-R, growth hormone secretagogue
receptor; TSH, thyroid stimulating hormone.
Unger, 2009) and a stimulating effect of ghrelin on FT4 secre-
tion in vivo (Kluge and Riedl, 2010), suggesting a reciprocal effect
between ghrelin and thyroid hormones. Since previous studies
were conducted in patients with abnormal thyroid hormone lev-
els (hyperthyroidism and hypothyroidism) they could not assess
the direct role of TSH on ghrelin secretion. The present study was
designed in athyreotic patients in stable replacement l-thyroxine
therapy and normal TSH to study the effect of exogenous TSH
administration independent of thyroid status.
PATIENTS AND METHODS
The study group included 50 patients (16 males and 34
females) submitted to total thyroidectomy and 131-iodine rem-
nant ablation for differentiated thyroid cancer. Mean age was
47.5± 16.5 years and mean BMI was 25.6± 5.01 kg/m2. Twenty-
eight patients with persistent disease or at high risk, received
l-thyroxine in suppressive or semisuppressive doses (target TSH
<0.5μIU/mL), 22 patients, who had previous evidence of com-
plete remission,were treatedwith replacement doses of l-thyroxine
aimed to maintain normal TSH concentration.
Patients were scheduled to receive rhTSH (Thyrogen; Genzyme
Therapeutics, Cambridge, MA, USA) for periodic staging of their
disease. rhTSHwas administrated at the dosage of 0.9mg i.m. once
daily for two consecutive days according to conventional protocol
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(Pacini and Ladenson, 2006). Blood samples were taken between
08.00 and 09.00 after a overnight fasting for measurement of TSH,
FT3, FT4, and ghrelin before the ﬁrst administration of rhTSH
and for measurement of only TSH and ghrelin 24, 48, 72, and 96 h
after the ﬁrst administration of rhTSH.
Serum total ghrelin was determined by a validated radioim-
munoassay (RIA; Mediagnost, Reutlingen, Germany) with a func-
tional sensitivity described by the manufacturer of 0.04 ng/ml;
the normal range is 600–1400 pg/ml. Serum TSH was deter-
mined by a commercially chemiluminescent assay (Immulite 2000,
third generation TSH, Los Angeles, CA, USA; EURO/DPC limited
Lamberies, Gwynedd, UK).
STATISTICAL ANALYSIS
Data are presented as mean± SD. Statistical analysis was per-
formed using the Mann–Whitney test when comparing non-
parametric data. Areas under the serum concentration curves
(AUC) of ghrelin and TSH were calculated for the intervals 0–
96 h by applying the trapezoid rule. One-way ANOVA was con-
ducted to compare serum ghrelin concentration at various time
points. Post hoc comparisons were conducted using Bonferroni’s
correction. Correlations between the variables were analyzed by
Pearson analysis using the Graph Pad Prism version 3.0. Statistical
signiﬁcance was deﬁned as p value< 0.05.
RESULTS
Mean± SD values of basal TSH were 0.54± 0.77μU/ml with-
out signiﬁcant difference between females andmales. As expected,
after rhTSH administration TSH concentrations increased at
24 and 48 h with peak TSH values ranging 20.2–313μU/ml
(mean± SD 98.4± 66.7μU/ml). In most patients (42 patients)
the peak serum TSH was observed 48 h after the second rhTSH
injection. The TSH–AUC was positively associated with age
(r = 0.55, p< 0.0001), but not with BMI. Mean± SD values
of basal ghrelin were 1085± 373 pg/ml without signiﬁcant dif-
ference between males and females. After rhTSH administra-
tion ghrelin concentrations decreased signiﬁcantly (p< 0.01) at
24 h (mean± SD 934± 314 pg/ml p< 0.01) and returned to pre-
treatment levels at 96 h (Figure 1). As shown in Figure 2 a
negative correlation between ghrelin AUC and BMI was observed
(r =−0.37, p = 0.008).
DISCUSSION
In vitro studies demonstrated that both ghrelin and GHR-S are
expressed in normal and neoplastic thyroid glands (Gnanapa-
van and Kola, 2002; Zhang and Wang, 2006; Karaoglu and Aydin,
2009; Ueberberg and Unger, 2009) and a reciprocal relationship
between thyroid hormones and ghrelin levels has been demon-
strated (Chrysanthia and Franchi, 2007). In vivo some stud-
ies have shown that ghrelin levels are reduced in overt hyper-
thyroidism, but not in subclinical hyperthyroidism (Tanda and
Lombardi, 2009), and are normalized after correction of hyper-
thyroidism (Riis and Hansen, 2003). However it is not clear
whether ghrelin reduction is a consequence of excess thyroid
hormones or secondary to the hyperinsulinemic status associ-
ated with hyperthyroidism (Gimenez-Palop and Gimenez-Perez,
FIGURE 1 | Changes of serum ghrelin concentrations after rhTSH
stimulation.
FIGURE 2 | Correlation between ghrelin AUC after rhTSH
administration and BMI.
2005). More conﬂicting data are reported in hypothyroid patients
with studies showing higher, normal, and even lower serum ghre-
lin levels (Gimenez-Palop and Gimenez-Perez, 2005; Altinova
and Toruner, 2006b; Gjedde and Vestergaard, 2008; Tanda and
Lombardi, 2009).
Our model of athyreotic patients replaced with l-thyroxine
consented to study the effect of TSH on ghrelin concentrations
independently of thyroid status. We observed a decrease of ghre-
lin levels in the ﬁrst 24 h from rhTSH administration return-
ing to baseline thereafter. We did not observe gender difference
in TSH-stimulated ghrelin concentrations, but, as expected, we
found a negative correlation between basal and TSH-stimulated
ghrelin levels and BMI. The observation that the correlation per-
sists also after TSH stimulation is an indication that the effect
of TSH is a true biological phenomenon rather than a fortu-
itous ﬁnding. Although we injected pharmacological doses of
rhTSH, we want to notice that the TSH levels achieved in the
blood are similar to those obtained after thyroid hormone with-
drawal in thyroid cancer patients undergoing routine follow-up
examination.
In conclusion, our study shows that a modulator action of TSH
is operating at gastric mucosa on ghrelin secretion, at least at acute
pharmacological doses.
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